Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis

<p><strong>Objective:</strong> Baricitinib is an oral selective inhibitor of Janus kinase (JAK) 1 and JAK2 that is efficacious in patients with rheumatoid arthritis (RA). This study analyzed changes in lymphocyte cell subsets during baricitinib treatment and correlated such changes...

Full description

Bibliographic Details
Main Authors:	Tanaka, Y, McInnes, I, Taylor, P, Byers, N, Chen, L, de Bono, S, Issa, M, Macias, W, Rogai, V, Rooney, T, Schlichting, D, Zuckerman, S, Emery, P
Format:	Journal article
Published:	John Wiley and Sons, Ltd. 2018

Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis

Similar Items